New Clinical Data Highlighting Foundation Medicine's Comprehensive Cancer Genomic Profile to be Presented at 2012 ASCO Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that new clinical data highlighting the company’s comprehensive cancer genomic profile and next-generation sequencing approach in clinical oncology will be presented at the 2012 Annual Meeting of the American Society for Clinical Oncology (ASCO) being held June 1-5, 2012 in Chicago.
“The data to be presented at ASCO support Foundation Medicine’s deep sequencing approach to simultaneously detect all classes of genomic alterations across hundreds of genes known to be related to cancer,” said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. “In our clinical experience abstract, this approach detected actionable alterations— those associated with available targeted treatments or ongoing clinical trials— for 74% of tumor samples in the study. Foundation Medicine’s test has also been shown to identify novel genomic alterations in multiple tumor types, including potentially druggable gene fusions. The combined evidence presented in these studies suggests that fully informative genomic profiling can now become a routine component of cancer patient care.”
The schedule for Foundation Medicine’s oral presentation is as follows:
| Date & Time: |
| Saturday, June 2 from 8:00 to 9:30 a.m. (CT); presentation from 9:00 a.m. to 9:15 a.m. (CT) |
| Session: | Clinical Science Symposium | |
| Abstract Number: | 7510 | |
| Title: | Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens. | |
| Location: | E Hall D2 | |
| Collaborator: | Dana-Farber Cancer Institute |
The schedule for Foundation Medicine’s poster discussion presentations is as follows:
| Date & Time: |
| Friday, June 1 from 1:00 to 5:00 p.m. (CT); discussion from 4:30 to 5:30 p.m. (CT) |
| Abstract Number: | 3533 | |
| Title: | Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC). | |
| Poster Number: | 25 | |
| Location: | E450b; discussion in E Arie Crown | |
| Collaborator: | Albany Medical College | |
| Date & Time: |
| Monday, June 4 from 1:15 to 5:15 p.m. (CT); discussion from 4:45 to 5:45 p.m. (CT) |
| Abstract Number: | 1015 | |
| Title: | Cancer gene profile of metastatic breast cancer. | |
| Poster Number: | 7 | |
| Location: | E450b; discussion in N Hall B1 | |
| Collaborator: | M.D. Anderson Cancer Center |
| Date & Time: |
| Tuesday, June 5 from 8:00 a.m. to 12:00 p.m. (CT); discussion from 11:30 a.m. to 12:30 p.m. (CT) |
| Abstract Number: | 7529 | |
| Title: | Concordance of driver mutations in primary and matched metastasis from patients with non-small cell lung cancer (NSCLC) using next-generation sequencing (NGS). | |
| Poster Number: | 19 | |
| Location: | E450a; discussion in E354a | |
| Collaborator: | Institut Gustav Roussy | |
| Date & Time: |
| Tuesday, June 5 from 8:00 a.m. to 12:00 p.m. (CT); discussion from 11:30 a.m. to 12:30 p.m. (CT) |
| Abstract Number: | 10524 | |
| Title: | Next-generation sequencing of FFPE solid tumor specimens for clinical use. | |
| Poster Number: | 17 | |
| Location: | S102; discussion in S100a | |
| Collaborator: | Memorial Sloan Kettering Cancer Center and University of California, San Francisco |
The schedule for Foundation Medicine’s general poster session presentations is as follows:
| Date & Time: |
| Sunday, June 3 from 8:00 a.m. to 12:00 p.m. (CT) |
| Abstract Number: | 4649 | |
| Title: | Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue. | |
| Poster Number: | 10H | |
| Location: | S Hall A2 | |
| Collaborator: | Weill Cornell Medical College | |
| Date & Time: |
| Monday, June 4 from 1:15 to 5:15 p.m. (CT) |
| Abstract Number: | 10559 | |
| Title: | Next-generation sequencing (NGS) detects high-frequency of targetable alterations in primary and metastatic breast cancer (MBC). | |
| Poster Number: | 44H | |
| Location: | S Hall A2 | |
| Collaborator: | M.D. Anderson Cancer Center |
| Date & Time: |
| Monday, June 4 from 1:15 to 5:15 p.m. (CT) |
| Abstract Number: | 10590 | |
| Title: | Next-generation sequencing (NGS) to identify actionable genomic changes in common and rare solid tumors: The FMI experience with the initial 50 consecutive patients. | |
| Poster Number: | 48G | |
| Location: | S Hall A2 |
About Foundation Medicine’s Comprehensive Cancer Genomic Profile
Foundation Medicine’s first clinical product is a fully informative genomic profile that complements traditional cancer treatment decision tools and often expands options by matching each patient with targeted therapies that are relevant to the molecular changes in their tumor. The profile is the first commercially available targeted sequencing assay utilizing clinical grade next-generation sequencing (NGS) in routine cancer specimens. Foundation Medicine’s assay identifies all classes of genomic alterations (including copy number alterations, insertions, deletions and rearrangements) in approximately 200 cancer-related genes. Genomic profile results are reported to the physician along with targeted therapies and clinical trials that may be relevant to each individual patient based on the most recent scientific and medical research. Foundation Medicine operates a CLIA-certified lab and will formally launch its commercial clinical laboratory services in mid-2012.
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company has developed a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit the company’s website www.foundationmedicine.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20120516006947/en/New-Clinical-Data-Highlighting-Foundation-Medicine%E2%80%99s-Comprehensive
Foundation Medicine Contact: Lee-Ann Murphy, 617-245-3077
pr@foundationmedicine.com
Source: Foundation Medicine